Vaccination against Lyme Disease with recombinant Borrelia burgdorferi outer-surface protein A (rOspA) in horses

Chang, Yung-Fu; Novosol, V.; McDonough, Sean P.; Chang, Chia‐Ming; Jacobson, Richard H.; Divers, Thomas J.; Quimby, Fred W.; Shin, Seung Uon; Lein, Donald H.

doi:10.1016/s0264-410x(99)00187-5

Cited by 31 publications

(46 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Each plate was read three times at 1-min intervals at an optical density at 650 nm (EL-312; Bio-Tek, Winooski, VT). The results were calculated by the KELA computer program and expressed as the slope of the reaction between the enzyme and the substrate to the amount of antibody bound (9,10).…”

Section: Methodsmentioning

confidence: 99%

Immunoprotection of Recombinant Leptospiral Immunoglobulin-Like Protein A against Leptospira interrogans Serovar Pomona Infection

et al. 2006

View full text Add to dashboard Cite

We previously reported the cloning and characterization of leptospiral immunoglobulin-like proteins LigA and LigB of Leptospira interrogans. LigA and LigB are conserved at the amino-terminal region but are variable at the carboxyl-terminal region. Here, we evaluate the potential of recombinant LigA (rLigA) as a vaccine candidate against infection by L. interrogans serovar Pomona in a hamster model. rLigA was truncated into conserved (rLigAcon) and variable (rLigAvar) regions and expressed in Escherichia coli as a fusion protein with glutathione-S-transferase (rLigA). Golden Syrian hamsters were immunized at 3 and 6 weeks of age with rLigA (rLigAcon and rLigAvar) with aluminum hydroxide as an adjuvant. Hamsters given recombinant glutathione-S-transferase (rGST)-adjuvant and phosphate-buffered saline-adjuvant served as nonvaccinated controls. Three weeks after the last vaccination, all animals were challenged intraperitoneally with 10 8 L. interrogans serovar Pomona bacteria (NVSL 1427-35-093002). All hamsters immunized with recombinant LigA survived after challenge and had no significant histopathological changes. In contrast, nonimmunized and rGSTimmunized hamsters were subjected to lethal doses, and the hamsters that survived showed severe tubulointerstitial nephritis. All vaccinated animals showed a rise in antibody titers against rLigA. Results from this study indicate that rLigA is a potential vaccine candidate against L. interrogans serovar Pomona infection.

show abstract

Section: Methodsmentioning

confidence: 99%

Immunoprotection of Recombinant Leptospiral Immunoglobulin-Like Protein A against Leptospira interrogans Serovar Pomona Infection

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Each plate was read three times at 650 nm at 1-min intervals (Biotek EL-312; Winooski, VT). The results were calculated by the KELA computer program and expressed as slope of the reaction between enzyme and substrate to amount of antibody bound (2,3).…”

Section: Methodsmentioning

confidence: 99%

Novel AttenuatedSalmonella entericaSerovar Choleraesuis Strains as Live Vaccine Candidates Generated by Signature-Tagged Mutagenesis

McDonough

Palaniappan

et al. 2005

Infect Immun

View full text Add to dashboard Cite

“…The pony described in this report was part of a larger group vaccinated with recombinant OspA vaccine three times at days 0, 20, and 82 as previously described (5).…”

Section: Methodsmentioning

confidence: 99%

“…Efforts have been made in the past several years to prevent Lyme disease by vaccination with either an outer surface protein A (OspA) recombinant vaccine (humans, dogs, and horses) or whole-cell bacterins (dogs) (4,5,11). Recently, we demonstrated that a recombinant OspA vaccine could protect ponies from infection when the animals were exposed to naturally infected ticks (5).…”

mentioning

confidence: 99%

Human Granulocytic Ehrlichiosis Agent Infection in a Pony Vaccinated with aBorrelia burgdorferiRecombinant OspA Vaccine and Challenged by Exposure to Naturally Infected Ticks

Chang¹,

McDonough²,

Chang³

et al. 2000

Clin Diagn Lab Immunol

View full text Add to dashboard Cite

A pony was vaccinated with recombinant OspA vaccine (rOspA) and then exposed 3 months later to Borrelia burgdorferi-infected ticks (Ixodes scapularis) collected in Westchester County, N.Y. At 2 weeks after tick exposure, the pony developed a high fever (105°F). Buffy coat smears showed that 20% of neutrophils contained ehrlichial inclusion bodies (morulae). Flunixin Meglumine (1 g daily) was given for 2 days, and the body temperature returned to normal. PCR for ehrlichial DNA was performed on blood samples for 10 consecutive days beginning when the pony was first febrile. This pony was monitored for another 3.5 months but developed no further clinical signs. The 44-kDa immunodominant human granulocytic ehrlichiosis antigen gene was amplified by PCR and cloned into a pCR2.1 vector. DNA sequence analysis of this gene showed it was only 8 bp different (99% identity) from the results reported by others (J.W. Ijdo et al., Infect. Immun. 66:3264-3269, 1998). Western blot analysis, growth inhibition assays, and repeated attempts to isolate B. burgdorferi all demonstrated the pony was protected against B. burgdorferi infection. These results highlight the potential for ticks to harbor and transmit several pathogens simultaneously, which further complicates the diagnosis and vaccination of these emerging tick-borne diseases.

show abstract

Vaccination against Lyme Disease with recombinant Borrelia burgdorferi outer-surface protein A (rOspA) in horses

Cited by 31 publications

References 44 publications

Immunoprotection of Recombinant Leptospiral Immunoglobulin-Like Protein A against Leptospira interrogans Serovar Pomona Infection

Immunoprotection of Recombinant Leptospiral Immunoglobulin-Like Protein A against Leptospira interrogans Serovar Pomona Infection

Novel AttenuatedSalmonella entericaSerovar Choleraesuis Strains as Live Vaccine Candidates Generated by Signature-Tagged Mutagenesis

Human Granulocytic Ehrlichiosis Agent Infection in a Pony Vaccinated with aBorrelia burgdorferiRecombinant OspA Vaccine and Challenged by Exposure to Naturally Infected Ticks

Contact Info

Product

Resources

About